The purpose of this study was to examine how gonadal steroid hormones modulate basal nociception and morphine antinociception relative to regulating reproduction in the adult rat. Male and female Sprague-Dawley rats were either gonadectomized (GDX) or shamgonadectomized (sham); GDX males were implanted subcutaneously with capsules containing testosterone (T), estradiol (E2), dihydrotestosterone (DHT), E2 and DHT, or nothing (0). GDX females received E2, T, or empty (0) capsules immediately after surgery, and vehicle or progesterone (P4) injections at 4-day intervals. Basal nociception and morphine antinociception were tested 28 days after surgery on 508C and 548C hotplate tests, and reproductive behavior and physiology were assessed shortly thereafter. There were no significant differences in baseline hotplate latencies among the male treatment groups, but morphine was significantly more potent in sham and GDX 1 T males than in GDX 1 0 males. The ability of T to increase morphine's potency was approximated by its major metabolites E2 and DHT, given together but not alone. Baseline hotplate latencies were higher in sham females tested during diestrus than in those tested during estrus. Morphine was significantly more potent in sham females tested during proestrus and diestrus than in those tested during estrus. Baseline hotplate latencies were significantly higher, and morphine was significantly less potent in GDX 1 E2, GDX 1 E2/P4 and GDX 1 T females than in GDX 1 0 females. All group differences in basal nociception and morphine antinociception observed on the 508C hotplate test were smaller and generally non-significant on the 548C hotplate test. Steroid manipulations produced the expected changes in reproductive behaviors and steroid-sensitive organs. These results demonstrate that in adult rats, gonadal steroid manipulations that are physiologically relevant, modulate (1) basal nociception in females but not males, and (2) morphine's antinociceptive potency in both males and females. q
Introduction
Numerous studies report sex differences in the analgesic effects of opioids. In humans, the mu agonist morphine (Sarton et al., 2000) and the mixed-action opioids pentazocine, butorphanol and nalbuphine (Gear et al., 1996a (Gear et al., ,b, 1999 (Gear et al., , 2000 produced greater or more prolonged analgesia in women than in men. Sex differences in opioid antinociception also are widely reported in rodents, although they tend to be in the opposite direction to those observed in humans. For example, morphine was significantly more potent or produced a greater effect in male than in female mice (Kavaliers and Innes, 1987; Lipa and Kavaliers, 1990; Candido et al., 1992) and rats (Baamonde et al., 1989; Cicero et al., 1996; Craft et al., 1999; Cook et al., 2000) . Variables that may influence the magnitude of sex differences in opioid antinociception in rodents include opioid efficacy/selectivity, intensity of the noxious stimulus used in the pain test, and subject genotype (i.e. rodent strain) (Kest et al., 1999; Mogil et al., 2000; Cook et al., 2000; Craft and Bernal, 2001; Barrett et al., 2002) . Sex differences in opioid analgesia have also been reported in the rhesus monkey (Negus and Mello, 1999, 2002) ; these sex differences are similar to those observed in rodent studies, using similar tests of acute thermal nociception. It is not yet known whether the opposite sex differences observed in human vs. animal studies reflect a true genotypic difference or are due to the different conditions under which opioid analgesia has been examined in human vs. animal subjects.
Sex differences in opioid antinociception are presumably due to the modulatory influence of gonadal steroid hormones, organizationally and/or activationally. Two recent studies have demonstrated organizational effects of gonadal steroids, such that neonatal gonadal steroid manip- 
